The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations.

##STR00001##

The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations.

##STR00001##

Disclosed herein are compounds of formula (I) ##STR00001##
and therapeutic methods of treatment with compounds of formula (I), wherein L.sup.1, L.sup.2, L.sup.4, R.sup.1, R.sup.4, R.sup.5, R.sup.6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Disclosed herein are compounds of formula (I) ##STR00001##
and therapeutic methods of treatment with compounds of formula (I), wherein L.sup.1, L.sup.2, L.sup.4, R.sup.1, R.sup.4, R.sup.5, R.sup.6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

[Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

A cyclic compound represented by Chemical Formula 1 and an organic light emitting device using the same, the compound used as a material of an organic material layer of the organic light emitting device and providing improved properties of efficiency, driving voltage, and lifetime characteristics of the organic light emitting device. ##STR00001##

The present invention relates to a method for synthesizing a compound of Formula (I)

##STR00001## as defined herein, comprising: (i) activating a compound of Formula (II)

##STR00002## as defined herein, by reacting said compound of Formula (II) with a compound of Formula (III)

##STR00003## as defined herein, in the presence of a base, to obtain a compound of Formula (IV)

##STR00004## as defined herein; and (ii) reacting the compound of Formula (IV) with an electrophile to obtain the compound of Formula (I). The present invention further relates to the organocatalysts used in the described methods and their respective uses.

The present invention relates to a method for synthesizing a compound of Formula (I)

##STR00001## as defined herein, comprising: (i) activating a compound of Formula (II)

##STR00002## as defined herein, by reacting said compound of Formula (II) with a compound of Formula (III)

##STR00003## as defined herein, in the presence of a base, to obtain a compound of Formula (IV)

##STR00004## as defined herein; and (ii) reacting the compound of Formula (IV) with an electrophile to obtain the compound of Formula (I). The present invention further relates to the organocatalysts used in the described methods and their respective uses.